Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

social media

- PMLiVE

Pfizer and BioNTech initiate phase 2 study of ‘enhanced’ COVID-19 vaccine

The vaccine is based on a version of the spike protein that the companies hope will offer better and broader protection against the virus

- PMLiVE

Pfizer and BioNTech speak out against CureVac suit over patents for COVID-19 vaccines

The civil suit claims that once CureVac had withdrawn its vaccine candidate, the company was unable to garner 50% efficacy in a late-stage trial

- PMLiVE

Fauci addresses need for pan-coronavirus and intranasal vaccines to combat COVID-19 variants

Vaccine manufacturers have been urged to move forward with producing Omicron-targeting formulations

- PMLiVE

Abstract Highlights from EHA 2022 : A Spotlight on Lymphoma

Spotlight on LymphomaAhead of EHA 2022, Medscape Education Chief Medical Officer, Hansa Bhargava, MD, caught up with Dr Loretta Nastoupil, US, on the most important abstracts to look out for in...

Medscape Education Global

Trust and transparency in Pharma & healthcare: impact of the COVID-19 pandemic

While it is obvious that trust in life science and healthcare companies is suboptimal, exactly how to improve the public’s trust is unclear...

Impetus Digital

- PMLiVE

WHO updates COVID-19 vaccination strategy to reach unprotected populations

The update raises targets to vaccinate 100% of healthcare workers and 100% of the highest risk populations with primary and booster doses

- PMLiVE

Gilead’s COVID-19 drug Veklury recommends for approval by CHMP

If approved by the EC, Veklury will become the only direct-acting antiviral with full marketing authorisation in the EU

- PMLiVE

Biopharma industry launches Berlin Declaration to ensure equal access during future pandemics

The Declaration outlines a framework that could help to ensure that lower-income countries receive pandemic vaccines and treatments

- PMLiVE

COVID-19 pandemic ‘reversed’ progress made in fight against antimicrobial resistance in US, new CDC report reveals

The report concluded that resistant hospital-onset infections and deaths both increased at least 15% during the first year of the pandemic

- PMLiVE

Elsevier launches global collaboration to ‘navigate’ changing landscape of scientific research

The initiative will examine the increased public attention on science during the COVID-19 pandemic and its impact on the academic research community

- PMLiVE

FDA grants Novavax’s COVID-19 vaccine emergency use authorisation for adults

The decision was based on data from a phase 3 trial which showed the vaccine was 90.4% effective in preventing mild, moderate or severe COVID-19

- PMLiVE

UK study reveals Omicron variant ‘substantially less likely’ to cause long Covid

The new study by King’s College London found that the odds of experiencing long COVID were between 20-50% less during the Omicron period versus the Delta period

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links